首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GDNF |
| Uniprot No | Q6UXV0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-351aa |
| 氨基酸序列 | SQTNNCTYLREQCLRDANGCKHAWRVMEDACNDSDPGDPCKMRNSSYCNLSIQYLVESNFQFKECLCTDDFYCTVNKLLGKKCINKSDNVKEDKFKWNLTTRSHHGFKGMWSCLEVAEACVGDVVCNAQLASYLKACSANGNPCDLKQCQAAIRFFYQNIPFNIAQMLAFCDCAQSDIPCQQSKEALHSKTCAVNMVPPPTCLSVIRSCQNDELCRRHYRTFQSKCWQRVTRKCHEDENCISTLSKQDLTCSGSDDCKAAYIDILGTVLQVQCTCRTITQSEESLCKIFQHMLHRKSCFNYPTLSNVKGMALYTRKHANKITLTGFHSPFNGE |
| 预测分子量 | 53.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于GDNF重组蛋白的经典文献摘要信息：
1. **文献名称**: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
**作者**: Lin LF, Doherty DH, Lile JD, et al.
**摘要**: 该研究首次报道了重组GDNF蛋白的克隆及功能验证，证明其能促进中脑多巴胺能神经元的存活，为帕金森病治疗提供了理论基础(Science, 1993)。
2. **文献名称**: Functional receptor for GDNF encoded by the c-ret proto-oncogene
**作者**: Durbec P, Marcos-Gutierrez CV, Kilkenny C, et al.
**摘要**: 揭示了GDNF通过c-Ret受体信号通路发挥作用，为重组GDNF在神经保护和再生机制研究提供关键分子机制(Nature, 1996)。
3. **文献名称**: GDNF rescues hyperalgesia in a rat model of neuropathic pain
**作者**: Boucher TJ, Okuse K, Bennett DL, et al.
**摘要**: 通过动物实验证明重组GDNF蛋白可逆转神经病理性疼痛模型的痛觉过敏，拓展了其在周围神经疾病治疗中的应用(Nature Medicine, 2000)。
4. **文献名称**: Recombinant human GDNF accelerates recovery of renal function in cisplatin-induced nephrotoxicity
**作者**: Garbay B, Boitier E, Robaglia-Schlupp A, et al.
**摘要**: 发现重组人源GDNF可减轻顺铂诱导的肾毒性损伤，提示其在器官保护中的潜在临床应用(Journal of the American Society of Nephrology, 2002)。
注：以上为基于领域经典文献的概括性描述，实际引用时建议通过PubMed或Web of Science核对原文信息。
Glial cell line-derived neurotrophic factor (GDNF) is a naturally occurring protein first identified in 1993 for its ability to promote the survival and differentiation of dopaminergic neurons. As a member of the transforming growth factor-β (TGF-β) superfamily, GDNF binds to a multi-component receptor system comprising the GDNF family receptor alpha-1 (GFRα1) and the RET proto-oncogene tyrosine kinase. This interaction activates downstream signaling pathways, including PI3K/AKT and MAPK, which regulate neuronal survival, growth, and synaptic plasticity.
GDNF plays critical roles in both the central and peripheral nervous systems. It supports motor neurons, enteric neurons, and renal development, making it a therapeutic candidate for neurodegenerative diseases like Parkinson’s disease (PD), where dopaminergic neuron degeneration is a hallmark. Preclinical studies in PD models demonstrated GDNF’s capacity to restore neuronal function, though clinical trials have shown mixed results, highlighting complexities in delivery methods and dosing.
Beyond neurodegeneration, GDNF is implicated in pain modulation, kidney morphogenesis, and spermatogenesis. However, its dual role in cancer—exhibiting both tumor-suppressive and promotive effects depending on context—has spurred ongoing research into its oncological applications.
Recombinant GDNF is produced using expression systems like *E. coli* or mammalian cell cultures, followed by purification to ensure bioactivity. Its therapeutic potential extends to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and spinal cord injuries. Challenges remain in optimizing its stability, targeted delivery, and minimizing off-target effects. Despite these hurdles, GDNF remains a cornerstone molecule in neuroregenerative research, bridging fundamental biology and translational medicine.
×
